147 related articles for article (PubMed ID: 8407887)
1. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics.
Nigam M; Seong CM; Qian Y; Hamilton AD; Sebti SM
J Biol Chem; 1993 Oct; 268(28):20695-8. PubMed ID: 8407887
[TBL] [Abstract][Full Text] [Related]
2. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.
Qian Y; Blaskovich MA; Saleem M; Seong CM; Wathen SP; Hamilton AD; Sebti SM
J Biol Chem; 1994 Apr; 269(17):12410-3. PubMed ID: 8175645
[TBL] [Abstract][Full Text] [Related]
3. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase.
Goldstein JL; Brown MS; Stradley SJ; Reiss Y; Gierasch LM
J Biol Chem; 1991 Aug; 266(24):15575-8. PubMed ID: 1874715
[TBL] [Abstract][Full Text] [Related]
4. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
Vogt A; Qian Y; Blaskovich MA; Fossum RD; Hamilton AD; Sebti SM
J Biol Chem; 1995 Jan; 270(2):660-4. PubMed ID: 7822292
[TBL] [Abstract][Full Text] [Related]
5. Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation.
Brown MS; Goldstein JL; Paris KJ; Burnier JP; Marsters JC
Proc Natl Acad Sci U S A; 1992 Sep; 89(17):8313-6. PubMed ID: 1518863
[TBL] [Abstract][Full Text] [Related]
6. Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase.
Reiss Y; Stradley SJ; Gierasch LM; Brown MS; Goldstein JL
Proc Natl Acad Sci U S A; 1991 Feb; 88(3):732-6. PubMed ID: 1992464
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase as a target for anticancer drug design.
Qian Y; Sebti SM; Hamilton AD
Biopolymers; 1997; 43(1):25-41. PubMed ID: 9174410
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
Qian Y; Vogt A; Sebti SM; Hamilton AD
J Med Chem; 1996 Jan; 39(1):217-23. PubMed ID: 8568811
[TBL] [Abstract][Full Text] [Related]
9. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.
James GL; Goldstein JL; Brown MS; Rawson TE; Somers TC; McDowell RS; Crowley CW; Lucas BK; Levinson AD; Marsters JC
Science; 1993 Jun; 260(5116):1937-42. PubMed ID: 8316834
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides.
Reiss Y; Goldstein JL; Seabra MC; Casey PJ; Brown MS
Cell; 1990 Jul; 62(1):81-8. PubMed ID: 2194674
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of farnesyltransferase and Ras processing peptidase.
Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
[TBL] [Abstract][Full Text] [Related]
12. Benzodiazepine peptidomimetic inhibitors of farnesyltransferase.
Marsters JC; McDowell RS; Reynolds ME; Oare DA; Somers TC; Stanley MS; Rawson TE; Struble ME; Burdick DJ; Chan KS
Bioorg Med Chem; 1994 Sep; 2(9):949-57. PubMed ID: 7712130
[TBL] [Abstract][Full Text] [Related]
13. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
Lerner EC; Qian Y; Blaskovich MA; Fossum RD; Vogt A; Sun J; Cox AD; Der CJ; Hamilton AD; Sebti SM
J Biol Chem; 1995 Nov; 270(45):26802-6. PubMed ID: 7592920
[TBL] [Abstract][Full Text] [Related]
14. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
[TBL] [Abstract][Full Text] [Related]
15. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors.
Qian Y; Marugan JJ; Fossum RD; Vogt A; Sebti SM; Hamilton AD
Bioorg Med Chem; 1999 Dec; 7(12):3011-24. PubMed ID: 10658608
[TBL] [Abstract][Full Text] [Related]
16. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.
James GL; Goldstein JL; Brown MS
J Biol Chem; 1995 Mar; 270(11):6221-6. PubMed ID: 7890759
[TBL] [Abstract][Full Text] [Related]
17. Pseudopeptide inhibitors of Ras farnesyl-protein transferase.
Graham SL; deSolms SJ; Giuliani EA; Kohl NE; Mosser SD; Oliff AI; Pompliano DL; Rands E; Breslin MJ; Deana AA
J Med Chem; 1994 Mar; 37(6):725-32. PubMed ID: 8145221
[TBL] [Abstract][Full Text] [Related]
18. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells.
Bishop WR; Bond R; Petrin J; Wang L; Patton R; Doll R; Njoroge G; Catino J; Schwartz J; Windsor W
J Biol Chem; 1995 Dec; 270(51):30611-8. PubMed ID: 8530497
[TBL] [Abstract][Full Text] [Related]
19. The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics.
Long SB; Hancock PJ; Kral AM; Hellinga HW; Beese LS
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):12948-53. PubMed ID: 11687658
[TBL] [Abstract][Full Text] [Related]
20. Pseudodipeptide inhibitors of protein farnesyltransferase.
deSolms SJ; Deana AA; Giuliani EA; Graham SL; Kohl NE; Mosser SD; Oliff AI; Pompliano DL; Rands E; Scholz TH
J Med Chem; 1995 Sep; 38(20):3967-71. PubMed ID: 7562930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
